

Certainty assessment							N: of patients		Effect		Certainty	Importance
N: of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fish oil, antioxidant-containing	standard	Relative (95% CI)	Absolute (95% CI)		
Mortality												
6	randomised trials	not serious	not serious	not serious	serious ^a	none	68/303 (22.4%)	55/304 (18.1%)	RR 1.23 (0.90 to 1.70)	42 more per 1,000 (from 18 fewer to 127 more)	⊕⊕⊕⊖ Moderate ^a	CRITICAL
ICU-LOS												
4	randomised trials	not serious	serious ^b	not serious	not serious	none	236	229	-	SMD 0.06 higher (0.13 lower to 0.24 higher)	⊕⊕⊕⊖ Moderate ^b	IMPORTANT
VFD(d)												
3	randomised trials	not serious	serious ^c	not serious	not serious	none	211	205	-	MD 0.7 lower (3.37 lower to 1.97 higher)	⊕⊕⊕⊖ Moderate ^c	IMPORTANT

CI: confidence interval; MD: mean difference; RR: risk ratio; SMD: standardised mean difference

Explanations

a. Confidence interval includes 1, indicating the possibility of no effect; thus, precision is limited.

b. Substantial heterogeneity across studies (I²=73%) with variable effect sizes.

c. Substantial heterogeneity across studies (I²= 72%) with variable effect sizes.

Supplement Fig. 32. GRADE Summary of Findings generated using GRADEpro GDT for anti-inflammatory lipid-containing enteral nutrition formulations in patients with ARDS and ALI (KQ19).